Table 1.
Characteristics of Included Studies
| Characteristic | Studies, No. (%) |
|---|---|
| Virus evaluated | |
| Influenza virus (A, B, H1N1, A, and B) | 134 (74.9) |
| RSV | 32 (17.9) |
| Adenovirus | 6 (3.4) |
| Human metapneumovirus | 5 (2.8) |
| Parainfluenza virus type 1–3 | 2 (1.1) |
| Population | |
| Children | 74 (41.3) |
| Adults | 14 (7.8) |
| Mixed/not reported | 91 (50.8) |
| Most frequently studied tests (company)a | |
| Influenza virus | |
| QuickVue Influenza A+B (Quidel) | 26 (14.5) |
| BinaxNOW Influenza A&B (Alere Scarborough) | 19 (10.6) |
| Directigen EZ FluA+B (Directigen-EZ, Becton Dickinson) | 16 (8.9) |
| Sofia Influenza A+B (Quidel) | 9 (5.0) |
| RSV | |
| BinaxNOW RSV (Alere Scarborough) | 6 (3.3) |
| BD Veritor RSV (BD Diagnostics) | 5 (2.8) |
| Sofia RSV (Quidel) | 4 (2.2) |
| Directigen EZ RSV (Becton Dickinson) | 3 (1.7) |
| Multiplex test | |
| mariPOC (ArcDia International) | 15 (8.4) |
| Other rapid tests | 77 (43.0) |
| Point-of-care testing | 47 (26.3) |
Abbreviation: RSV, respiratory syncytial virus.